MabCure Statistics
Total Valuation
MabCure has a market cap or net worth of 78,109.
| Market Cap | 78,109 |
| Enterprise Value | n/a |
Important Dates
| Earnings Date | n/a |
| Ex-Dividend Date | n/a |
Share Statistics
MabCure has 781.09 million shares outstanding.
| Current Share Class | 781.09M |
| Shares Outstanding | 781.09M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | +0.79% |
| Owned by Insiders (%) | n/a |
| Owned by Institutions (%) | n/a |
| Float | n/a |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.16 |
| PB Ratio | 0.02 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.17, with a Debt / Equity ratio of 0.08.
| Current Ratio | 0.17 |
| Quick Ratio | 0.16 |
| Debt / Equity | 0.08 |
| Debt / EBITDA | n/a |
| Debt / FCF | -4.87 |
| Interest Coverage | -3.80 |
Financial Efficiency
Return on equity (ROE) is -125.15% and return on invested capital (ROIC) is -4.41%.
| Return on Equity (ROE) | -125.15% |
| Return on Assets (ROA) | -4.22% |
| Return on Invested Capital (ROIC) | -4.41% |
| Return on Capital Employed (ROCE) | -18.31% |
| Weighted Average Cost of Capital (WACC) | 50.78% |
| Revenue Per Employee | 166,667 |
| Profits Per Employee | -4.09M |
| Employee Count | 3 |
| Asset Turnover | 0.05 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +9,900.00% in the last 52 weeks. The beta is 10.18, so MabCure's price volatility has been higher than the market average.
| Beta (5Y) | 10.18 |
| 52-Week Price Change | +9,900.00% |
| 50-Day Moving Average | 0.00 |
| 200-Day Moving Average | 0.00 |
| Relative Strength Index (RSI) | 47.80 |
| Average Volume (20 Days) | 51,106 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 0.00 |
Income Statement
In the last 12 months, MabCure had revenue of 500,000 and -12.26 million in losses. Loss per share was -0.19.
| Revenue | 500,000 |
| Gross Profit | 500,000 |
| Operating Income | -709,745 |
| Pretax Income | -12.26M |
| Net Income | -12.26M |
| EBITDA | -677,088 |
| EBIT | -709,745 |
| Loss Per Share | -0.19 |
Balance Sheet
The company has 146,436 in cash and 304,975 in debt, with a net cash position of -158,539 or -0.00 per share.
| Cash & Cash Equivalents | 146,436 |
| Total Debt | 304,975 |
| Net Cash | -158,539 |
| Net Cash Per Share | -0.00 |
| Equity (Book Value) | 3.88M |
| Book Value Per Share | 0.06 |
| Working Capital | -775,939 |
Cash Flow
In the last 12 months, operating cash flow was -61,387 and capital expenditures -1,265, giving a free cash flow of -62,652.
| Operating Cash Flow | -61,387 |
| Capital Expenditures | -1,265 |
| Free Cash Flow | -62,652 |
| FCF Per Share | -0.00 |
Margins
| Gross Margin | 100.00% |
| Operating Margin | -141.95% |
| Pretax Margin | -2,452.97% |
| Profit Margin | n/a |
| EBITDA Margin | -135.42% |
| EBIT Margin | -141.95% |
| FCF Margin | n/a |
Dividends & Yields
MabCure does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -2.09% |
| Shareholder Yield | -2.09% |
| Earnings Yield | -15,702.20% |
| FCF Yield | -80.21% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on November 26, 2007. It was a forward split with a ratio of 20.
| Last Split Date | Nov 26, 2007 |
| Split Type | Forward |
| Split Ratio | 20 |
Scores
MabCure has an Altman Z-Score of 3.68 and a Piotroski F-Score of 2.
| Altman Z-Score | 3.68 |
| Piotroski F-Score | 2 |